Optimizing Immune Checkpoint Inhibitors in Early-Stage Cancer Treatment Through Multidisciplinary Collaboration

Release Date: July 29, 2022

Expiration Date: July 29, 2023

Activity Overview

The use of immune checkpoint inhibitors (ICIs) has been well established in metastatic disease, leading to their investigation for use in earlier stages of cancer. Currently, few ICIs are approved for neoadjuvant and adjuvant indications, though clinical trials are underway in melanoma, non−small cell lung cancer, renal cell carcinoma, and other malignancies. In this multidisciplinary panel discussion, experts will review efficacy and safety data supporting the role of ICIs in early-stage cancers and strategies to overcome challenges associated with their therapeutic uptake. The panelists will explore patient populations likely to benefit from early initiation of ICIs in therapy, considerations for initiation and duration of therapy, as well as criteria to determine benefit for patients. The pharmacist’s role and considerations for management of immune-related adverse effects for patients receiving ICIs in the adjuvant setting compared with the metastatic setting will also be discussed.

Target Audience

This activity is designed to educate medical oncologists, oncology nurses, and oncology pharmacists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explore the current and emerging uses of immune checkpoint inhibitors (ICIs) in early stages of cancer and supportive clinical data
• Compare challenges in integrating ICIs into early-stage cancers among oncologists, oncology nurses, and oncology pharmacists
• Explain the importance of prompt immune-related adverse effect (irAE) identification in early-stage cancers
• Develop a plan to monitor and manage irAEs that incorporates collaboration among oncologists, nurses, and pharmacists on the multidisciplinary cancer care team

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

The staff at Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
Pharmacy Times Continuing Education - PTCE

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.